There has been a high demand for weight loss medications considering the high rates of obesity in the United States. A dire need exists for more options in treatment for the fight against obesity. According to the CDC, 17% of children and teens and greater than 1/3 of adults are obese. However, hope is on the horizon. Two medications have recently been approved: Belviq and Qysmia. This four part series will focus on these medications, their side effects, and key considerations to help you to make the right choices.
Belviq is a medication which works by decreasing the appetite. However, the pill itself isn’t the cure all. In addition to taking this medication, it is important to have a regular exercise plan and a targeted diet with fewer calories than usual. Weight loss requires nutrition, exercise, and mental readiness with motivation. You must be motivated to adhere to a healthy diet and exercise regularly.
In addition, the criteria include a BMI of 27 to 30 or greater than 30. Know your BMI prior to starting this medication. Consult your healthcare provider to discuss your BMI.
According to the FDA report, there is a warning that Belviq causes side effects related to serotonin and its receptors, a chemical in the gut and nervous system connected with many illnesses. It was also noted in the same report that Fen Phen was pulled off the shelves in 1997 due to a serotonin-receptor reaction on the heart leading to valve problems. Consult your healthcare provider. It is important to have a review of medications, especially for a look at those connected with serotonin if considering Belviq.
Fighting obesity also means a fight against chronic illnesses. Chronic illness can negatively affect our overall quality of life. The more weapons that you have, the closer you will be to victory. If you want to enlist Belviq to help in your own personal obesity fight, make sure you remain healthy and safe in your battle.
Stay tuned to the work of D.M. Blake for more health information. Coming soon: A look at Qysmia, a weight loss medication approved July, 2012.
Each one teach one: share this article with family, friends, and colleagues
D.M. Blake is a Family Nurse Practitioner with 18 years of experience in healthcare in a variety of fields, an author, editor, copywriter, freelance writer, and screenwriter. She is author of the quarterly “AfricAm Health Focus Newsletter” written for the public. Visit http://www.dmbauthor.com/. Follow her on Twitter at “DMBlake, Author.” Subscribe to her blog at http://authordmblake.wordpress.com.